Intravitreal Bevacizumab for Retinal Disorders

• Status: Unknown status
• Trial end date: 2006-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Bevacizumab is an anti-VEGF agent used in approved for use in metastatic colorectal carcinoma (FDA Approved). This study analyzes the safety and efficacy of off-label Intravitreal Injection of bevacizumab (Avastin) for CNVM, Macular oedema due to diabetic retinopathy, vascular occlusion and other retinal disorders.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Narayana Nethralaya
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Age related macular degeneration with Juxtafoveal and Subfoveal CNVM: Recurrent CNVM following PDT and TTT with IVTA. Patient who could not afford PDT, Macugen or Lucentis which is FDA approved.

• Myopic CNVM, Idiopathic CNVM, Inflammatory CNVM and other conditions associated with CNVM.

• Refractory macular oedema due to vein occlusion, Pseudophakia, Clinically significant macular oedema (CSME) etc. that affects vision and does not respond adequately to usual treatment methods.

• Proliferative diabetic retinopathy, non-resolving vitreous haemorrhage with PDR.

Exclusion Criteria:

• Patients with poor compliance

• Patients with uncontrolled diabetes and hypertension or any other medical condition that increase the risk of complications like recent history of Stroke or myocardial infraction (< one year). (Physician clearance was obtained for all patients).

• Patients who had undergone major surgery 28 days before, were excluded from the study and it was also suspended prior to elective surgery.